title: Tumor necrosis factor alpha regulates CXC chemokine receptor expression and function.
abstract: The alpha chemokine family is central to the participation of neutrophils in the acute inflammatory response. These substances interact with neutrophils through two cell surface receptors, CXCR-1 and CXCR-2 (formally known as IL-8R-1 and IL-8R-2). We investigated the possible regulatory effects of tumor necrosis factor alpha (TNFalpha) pretreatment on CXCR-1 and CXCR-2. To this end, we examined these receptors with flow cytometry, radioligand binding, Northern blot analyzes, calcium mobilization, and chemotaxis experiments on human neutrophils. In flow cytometry experiments, TNFalpha pretreatment substantially decreased cell surface CXCR-2 receptor levels but showed partial recovery at 120 min. On the other hand, CXCR-1 receptor levels had a sharp decline at 15 min and maintained that level to 120 min. Northern blot analyzes showed that mRNA levels of both IL-8 receptors were essentially unchanged after 45 min of TNFalpha pretreatment, but declined markedly following 2 h of pretreatment. Chemotaxis experiments on cells treated with TNFalpha for 5-120 min showed a substantial down-regulation of chemotaxis to IL-8 and GROalpha. This was noted to be much greater than the decline in cell surface receptors. Calcium mobilization experiments revealed minimal inhibition of the IL-8-induced increase in calcium after pretreatment with TNFalpha, but the response to NAP-2 was substantially inhibited. The data demonstrate differential regulation of the IL-8 receptor.
authors.affiliation: Department of Surgery, University of Cincinnati, College of Medicine, Ohio 45267, USA.
authors.forename: R S
authors.initials: RS
authors.lastname: Jawa
authors.forename: G A
authors.initials: GA
authors.lastname: Quaid
authors.forename: M A
authors.initials: MA
authors.lastname: Williams
authors.forename: C M
authors.initials: CM
authors.lastname: Cave
authors.forename: C T
authors.initials: CT
authors.lastname: Robinson
authors.forename: G F
authors.initials: GF
authors.lastname: Babcock
authors.forename: M A
authors.initials: MA
authors.lastname: Lieberman
authors.forename: D
authors.initials: D
authors.lastname: Witt
authors.forename: J S
authors.initials: JS
authors.lastname: Solomkin
mesh_terms: D015152:Blotting, Northern; D002118:Calcium / Q000378:metabolism; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D002633:Chemotaxis; D015536:Down-Regulation; D005434:Flow Cytometry; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism*; D010455:Peptides / Q000378:metabolism; D012333:RNA, Messenger; D054389:Receptors, CCR1; D054390:Receptors, CCR2; D019707:Receptors, Chemokine / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism* / Q000494:pharmacology; D001620:beta-Thromboglobulin
chemical_list: C515300:CCR1 protein, human; C515334:CCR2 protein, human; D016209:Interleukin-8; C061615:PPBP protein, human; D010455:Peptides; D012333:RNA, Messenger; D054389:Receptors, CCR1; D054390:Receptors, CCR2; D019707:Receptors, Chemokine; D014409:Tumor Necrosis Factor-alpha; D001620:beta-Thromboglobulin; C009862:connective tissue-activating peptide; D002118:Calcium